Rondo Therapeutics
About Rondo Therapeutics
Develops bispecific therapeutic antibodies that engage immune cells to target and eliminate solid tumors, particularly those resistant to immune checkpoint inhibitors. By optimizing the potencies of immune-engaging arms and improving tumor localization, these antibodies aim to provide effective treatment with reduced side effects, addressing critical gaps in cancer immunotherapy.
```xml <problem> Many solid tumors are resistant to existing immune checkpoint inhibitors, leaving a significant unmet need for effective cancer immunotherapies. Traditional bispecific antibody designs optimized for blood cancers often fail to translate effectively to solid tumors due to dose-limiting toxicities and poor tumor localization. </problem> <solution> Rondo Therapeutics develops next-generation, immune-cell engaging bispecific antibodies engineered to target and eliminate solid tumors. Their antibodies are designed to maximize efficacy while minimizing side effects by tuning the potencies of immune-engaging arms and improving tumor localization. This approach aims to provide clinicians with flexible dosing strategies and combination regimens to deliver optimal results for patients with solid tumors. The company utilizes NGS-based antibody discovery to rapidly develop diverse binding arm collections and employs proprietary functional and developability screens to identify clinically viable molecules. </solution> <features> - Bispecific antibodies designed to engage immune cells and target solid tumors - Optimized therapeutic window to maximize efficacy and minimize dose-limiting toxicities - Tuned potencies of immune-engaging arms for improved safety and efficacy - Enhanced tumor localization to concentrate immune activity at the tumor site - Fixed-light chain format allows for flexible pairing of immune effector and tumor-targeting arms - NGS-based antibody discovery for rapid development of diverse binding arm collections - Proprietary functional and developability screens to identify clinically viable molecules - Multi-product pipeline targeting a range of solid tumor indications, including bladder and ovarian cancer </features> <target_audience> The primary target audience includes clinicians treating solid tumors, as well as pharmaceutical companies seeking strategic partnerships for synergistic advancement of clinical assets. </target_audience> ```
What does Rondo Therapeutics do?
Develops bispecific therapeutic antibodies that engage immune cells to target and eliminate solid tumors, particularly those resistant to immune checkpoint inhibitors. By optimizing the potencies of immune-engaging arms and improving tumor localization, these antibodies aim to provide effective treatment with reduced side effects, addressing critical gaps in cancer immunotherapy.
Where is Rondo Therapeutics located?
Rondo Therapeutics is based in Hayward, United States.
When was Rondo Therapeutics founded?
Rondo Therapeutics was founded in 2021.
How much funding has Rondo Therapeutics raised?
Rondo Therapeutics has raised 67000000.
- Location
- Hayward, United States
- Founded
- 2021
- Funding
- 67000000
- Employees
- 23 employees
- Major Investors
- Red Tree Venture Capital, Canaan Partners